AI주식인사이트AI Stock Insight
C

메지온

140410KOSDAQ자연과학 및 공학 연구개발업

41.5 / 100

Reference Date: 2026-04-13

Financial Score15.0 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is low with sound financial health but Revenue is on a declining trend. Plunged 30.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Meizon is a pharmaceutical company established in 2002, focusing on global new drug development for various diseases, including erectile dysfunction and single-ventricle syndrome treatments. Although it submitted a New Drug Application (NDA) to the FDA for a single-ventricle syndrome treatment in 2021, the application was temporarily withdrawn following a request for additional clinical trials, and the company is now proceeding with the additional trial process.

Number of Employees

18people

Average Salary

63.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 120.074.0Point
PBR
—Industry Average 3.823.5Point
ROE
-110.44Industry Average -32.113.5Point

3.4x industry avg (excellent)

Debt Ratio
7.31Industry Average 7.524.0Point

In line with industry avg

Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼40.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼8.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -58.6% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (38%)

Current 87,100Won52-week high 172,70052-week low 32,500
1-month return0.0Point

1m -30.15% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral정기주주총회결과2026-03-30
  • Neutral사업보고서 (2025.12)2026-03-20
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-18
  • Neutral감사보고서제출2026-03-16
  • Neutral파생상품거래손실발생2026-03-16